We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+12.11%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$177M
AUM Growth
-$47.3M
Cap. Flow
-$28.6M
Cap. Flow %
-16.14%
Top 10 Hldgs %
37.39%
Holding
117
New
21
Increased
27
Reduced
33
Closed
35

Top Buys

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$3.68M
2
FULC icon
Fulcrum Therapeutics
FULC
+$3.52M
3
CERS icon
Cerus
CERS
+$3.5M
4
ARVN icon
Arvinas
ARVN
+$3.29M
5
NXTC icon
NextCure
NXTC
+$3.18M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$12.8M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$5.49M
3
MGNX icon
MacroGenics
MGNX
+$4.75M
4
VSTM icon
Verastem
VSTM
+$4.27M
5
TCRR
TCR2 Therapeutics Inc. Common Stock
TCRR
+$3.09M

Sector Composition

Rank Sector Weight
1 Healthcare 90.54%
2 Financials 5.83%
3 Miscellaneous 2.47%
4 Industrials 1.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BHVN
1
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$8.6M 4.86%
61,897
+5,271
+9% +$658K
VCYT icon
2
Veracyte
VCYT
$3.48B
$8.34M 4.72%
179,548
+28,687
+19% +$1.25M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.13M 4.59%
45,941
+8,188
+22% +$1.32M
MRUS
4
DELISTED
Merus
MRUS
$7.61M 4.3%
345,964
+25,149
+8% +$539K
AMYT
5
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$6.22M 3.52%
516,221
+59,684
+13% +$674K
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$5.75M 3.25%
52,469
+2,434
+5% +$253K
COGT icon
7
Cogent Biosciences
COGT
$6.02B
$5.7M 3.22%
677,900
+479,655
+242% +$3.68M
IMTX icon
8
Immatics
IMTX
$1.44B
$5.69M 3.22%
437,866
+148,458
+51% +$1.89M
FULC icon
9
Fulcrum Therapeutics
FULC
$294M
$5.24M 2.96%
+185,691
New +$3.52M
NXTC icon
10
NextCure
NXTC
$27.9M
$4.86M 2.75%
60,109
+36,317
+153% +$3.18M
INSM icon
11
Insmed
INSM
$25.9B
$4.81M 2.72%
174,588
-2,845
-2% -$74.6K
RACB
12
DELISTED
Research Alliance Corp. II Class A Common Stock
RACB
$4.66M 2.64%
473,396
-22,459
-5% -$222K
UTHR icon
13
United Therapeutics
UTHR
$22.1B
$3.91M 2.21%
21,189
+5,900
+39% +$1.16M
ITCI
14
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$3.8M 2.15%
101,890
-11,368
-10% -$395K
CERS icon
15
Cerus
CERS
$534M
$3.77M 2.13%
619,369
+600,678
+3,214% +$3.5M
IMGN
16
DELISTED
Immunogen Inc
IMGN
$3.69M 2.08%
649,919
-177,668
-21% -$1.03M
SRRA
17
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.58M 2.03%
163,486
+24,181
+17% +$484K
MORF
18
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$3.27M 1.85%
57,704
-46,154
-44% -$2.79M
ITOS
19
DELISTED
iTeos Therapeutics
ITOS
$3.16M 1.78%
116,931
+41,420
+55% +$1.08M
ACRS icon
20
Aclaris Therapeutics
ACRS
$885M
$3.12M 1.76%
173,327
-15,392
-8% -$247K
ARVN icon
21
Arvinas
ARVN
$600M
$3.06M 1.73%
+37,249
New +$3.29M
CYPH
22
Cypherpunk Technologies Inc
CYPH
$184M
$2.49M 1.41%
+62,000
New +$1.17M
HALO icon
23
Halozyme
HALO
$12B
$2.45M 1.38%
60,170
-6,503
-10% -$272K
CCXI
24
PUT
DELISTED
ChemoCentryx, Inc.
CCXI
$2.38M 1.35%
139,200
+39,200
+39% +$611K
BLU
25
DELISTED
BELLUS Health Inc.
BLU
$2.24M 1.27%
365,000
+155,067
+74% +$588K
1
2 3 4 5

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Silverarc Capital Management held 117 positions worth $177M, down 21% from $224M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Silverarc Capital Management withdrew a net $28.6M in Q3 2021, closing 35 positions and reducing 33 holdings. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $12.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 85% a quarter earlier, followed by Financials and Miscellaneous.

Against the trend, Silverarc Capital Management opened a new position in Fulcrum Therapeutics worth $5.24M.

  • Silverarc Capital Management's largest Q3 2021 buy was Fulcrum Therapeutics: 185,691 shares worth $5.24M.
  • Silverarc Capital Management added most to Cogent Biosciences in Q3 2021, an estimated $3.68M increase.
  • Silverarc Capital Management's biggest Q3 2021 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $5.49M.
  • Silverarc Capital Management fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2021, selling an estimated $12.8M.
  • Silverarc Capital Management's ten largest holdings make up 37% of its $177M portfolio in Q3 2021.
  • Silverarc Capital Management opened 21 new positions and closed 35 in Q3 2021.
  • Silverarc Capital Management's portfolio value fell 21% quarter-over-quarter to $177M.

Based on Silverarc Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.